Share on StockTwits

Epizyme (NASDAQ:EPZM) CFO Jason P. Rhodes sold 30,000 shares of the stock in a transaction dated Monday, July 7th. The stock was sold at an average price of $32.74, for a total transaction of $982,200.00. Following the transaction, the chief financial officer now directly owns 70,000 shares in the company, valued at approximately $2,291,800. The transaction was disclosed in a filing with the SEC, which is available at this link.

Epizyme (NASDAQ:EPZM) traded up 2.80% during mid-day trading on Wednesday, hitting $30.85. The stock had a trading volume of 164,607 shares. Epizyme has a 52 week low of $18.10 and a 52 week high of $45.72. The stock has a 50-day moving average of $26.91 and a 200-day moving average of $26.84. The company’s market cap is $1.015 billion.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.47) by $0.25. On average, analysts predict that Epizyme will post $-1.78 earnings per share for the current fiscal year.

Separately, analysts at Zacks upgraded shares of Epizyme from a “neutral” rating to an “outperform” rating in a research note on Wednesday. They now have a $35.10 price target on the stock.

Epizyme, Inc is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.